Publications by authors named "Ken Culver"

Claim this Profile
P
Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States.
Hannah Le, Josh Coulter, Ken Culver, Joseph C Cappelleri, Nada Rifi

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts.
Nancee Pronsati, Geoffrey Liu, Todd M Bauer, Enriqueta Felip, Yasushi Goto, Ken Culver

Lung Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and outcomes in patients with metastatic synovial sarcoma in France, Germany, Italy, Spain and the UK.
Nashita Patel, Shibani Pokras, Jane Ferma, Vicky Casey, Fil Manuguid, Ken Culver

Future Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and outcomes in metastatic synovial sarcoma: a real-world study in the US oncology network.
Shibani Pokras, Wan-Yu Tseng, Janet L Espirito, April Beeks, Ken Culver

Future Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Qualitative study to characterize patient experience and relevance of patient-reported outcome measures for patients with metastatic synovial sarcoma.
Laurie Eliason, Laura Grant, Anya Francis, Anna Cardellino, Ken Culver

J Patient Rep Outcomes· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
Leora Horn, Joshua Bauml, Patrick M Forde, Keith L Davis, Nathaniel J Myall, Ken Culver

Lung Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
Zheng-Yi Zhou, Alex Mutebi, Simeng Han, Arielle G Bensimon, Marie Louise Ricculli, Ken Culver

J Med Econ· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.
Michael K Wong, Eric Jonasch, Sumanta K Pal, James E Signorovitch, Peggy L Lin, Ken Culver

Expert Opin Pharmacother· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.
James E Signorovitch, Nicholas J Vogelzang, Sumanta K Pal, Peggy L Lin, Daniel J George, Ken Culver

Curr Med Res Opin· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Eric Jonasch, James E Signorovitch, Peggy L Lin, Zhimei Liu, Ken Culver

Curr Med Res Opin· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis